Venous Thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is one of the leading causes of death and morbidity in hospitalized patients and is the most common preventable cause of inpatient death1. In fact, after coronary heart disease and stroke, VTE is the most common cause of cardiovascular death and disability each year2.
The Cost of VTE
- Nearly $40 billion is spent treating preventable, hospital-acquired VTE each year3
- Over $19 billion is spent treating the long-term effects of hospital-acquired VTE3
- The incremental inpatient costs from treating a preventable VTE event are approximately $10,000 per DVT event and $20,000 per PE event4
Though effective preventative measures are widely available, only 50% of all at-risk patients (which is sometimes up to half of all hospital inpatients) receive adequate preventative care1. Solutions like our Flowtron® garments not only provide comfort and compliance, they can significantly and safely reduce the incidence of VTE.
Download the clinical evidence brochure to learn how to prevent VTE with Flowtron DVT Prophylaxis Systems.
- Cohen AT, Tapson VF, Bergman J-F et al. Venous thromboembolism and prophylaxis in the acute hospital setting (ENDORSE study): A multinational cross-sectional study. Lancet. 2008; 371: 387-394.
- Lowe G. Epidemiology of venous thromboembolism: the need for large (including prospective) studies and meta-analyses. J Thromb Haemost.2012;10:2186-2188.
- Mahan CE, Borrego ME, Woershing AL et al. Venous thromboembolism: Annualised United States model for total, hospital acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.
- Maynard G, Stein J. Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement. Prepared by the Society of Hospital Medicine. AHRQ Publication No. 08-0075. Rockville, MD: Agency for Healthcare Research and Quality. August 2008.